A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Autor: Nademanee, Auayporn *, Forman, Stephen, Molina, Arturo, Fung, Henry, Smith, David, Dagis, Andy, Kwok, Cheuk, Yamauchi, Dave, Anderson, Anne-Line, Falk, Peter, Krishnan, Amrita, Kirschbaum, Mark, Kogut, Neil, Nakamura, Ryotaro, O'Donnell, Margaret, Parker, Pablo, Popplewell, Leslie, Pullarkat, Vinod, Rodriguez, Roberto, Sahebi, Firoozeh, Smith, Eileen, Snyder, David, Stein, Anthony, Spielberger, Ricardo, Zain, Jasmine, White, Christine, Raubitschek, Andrew
Zdroj: In Blood 15 October 2005 106(8):2896-2902
Databáze: ScienceDirect